middle.news

How Safe Is Nyrada’s Xolatryp? Phase I Trial Offers Clear Answers

9:48am on Wednesday 6th of August, 2025 AEST Biotechnology
Read Story

How Safe Is Nyrada’s Xolatryp? Phase I Trial Offers Clear Answers

9:48am on Wednesday 6th of August, 2025 AEST
Key Points
  • Phase I trial completed with 48 healthy volunteers
  • No dose-limiting toxicities or serious adverse events observed
  • Pharmacokinetics show predictable, linear dosing up to double dose
  • Data cleaning and database lock expected by August 2025
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Nyrada (ASX:NYR)
OPEN ARTICLE